In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats

1 The thymoleptic drug citalopram (CIT) belongs to the selective serotonin reuptake inhibitors (SSRIs) and is today extensively used in psychiatry. Fu rther clarification of the enantiomer-selective distribution of racemic CIT in both clinical and toxic doses is highly warranted; 2 By a steady-state in vivo paradigm, rats underwent chronic systemic expos ure for 10 days by using osmotic pumps and the total as well as the individ ual distributions of the S- and R-enantiomers of CIT, and its metabolites i n serum and two different brain regions, were analysed. 3 In serum, the S/R ratios in the groups treated with 10, 20, or 100 mg kg( -1) day(-1) were 0.94, 0.83, and 0.34, respectively. The ratios were almost the same in the brain regions. 4 In the group treated with 100 mg kg(-1) day(-1), the serum and brain tota l CIT levels were found to be 20 times and 6-8 times higher than in the rat s treated with 10 or 20 mg kg(-1) day(-1), respectively. In all groups, the CIT levels were higher in brain tissue as compared to serum. 5 In a spontaneous open-field behavioural test, a correlation between clini cal and toxic drug concentrations was observed. 6 In conclusion, the R-enantiomer was present in an increased proportion co mpared with the S-enantiomer when higher steady-state CIT concentration was prevailing. This is of particular interest, since the S-enantiomer is resp onsible for the inhibition of serotonin reuptake in vitro. The present data may be of importance, as full understanding on where different racemic or enantiomeric drug effects of CIT and its main metabolites are unravelled.